文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

胆汁淤积性肝病管理指南（2021 年）

Guidelines for the Management of Cholestatic Liver Diseases (2021).

作者信息

Lu Lungen

机构信息

Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

出版信息

J Clin Transl Hepatol. 2022 Aug 28;10(4):757-769. doi: 10.14218/JCTH.2022.00147. Epub 2022 Apr 29.

DOI:10.14218/JCTH.2022.00147
PMID:36062287
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9396310/
Abstract

In 2015, the Chinese Society of Hepatology and the Chinese Society of Gastroenterology issued a consensus statement on the diagnosis and management of cholestatic liver diseases. More clinical data on this topic have appeared during recent years. The Autoimmune Liver Disease Group of the Chinese Society of Hepatology organized an expert group to review recent evidence and provide an update to these previous guidelines. Herein, we provide 22 recommendations as a working reference for the management of cholestatic liver diseases by clinical practitioners.

摘要

2015年，中华医学会肝病学分会和中华医学会消化病学分会发布了关于胆汁淤积性肝病诊断和管理的共识声明。近年来，关于该主题的更多临床数据已经出现。中华医学会肝病学分会自身免疫性肝病学组组织了一个专家组来审查近期证据，并对这些先前的指南进行更新。在此，我们提供22条建议，作为临床医生管理胆汁淤积性肝病的工作参考。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e20/9396310/af5f4c8b59ed/JCTH-10-757-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e20/9396310/872c26b4c54e/JCTH-10-757-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e20/9396310/af5f4c8b59ed/JCTH-10-757-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e20/9396310/872c26b4c54e/JCTH-10-757-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e20/9396310/af5f4c8b59ed/JCTH-10-757-g002.jpg

相似文献

[1]
Guidelines for the Management of Cholestatic Liver Diseases (2021).

J Clin Transl Hepatol. 2022-8-28

[2]
[Guidelines on the management of cholestasis liver diseases (2021)].

Zhonghua Gan Zang Bing Za Zhi. 2022-3-20

[3]
[Guidelines on the management of cholestasis liver diseases (2021)].

Zhonghua Nei Ke Za Zhi. 2021-12-1

[4]
[Guidelines on the diagnosis and management of primary sclerosing cholangitis (2021)].

Zhonghua Gan Zang Bing Za Zhi. 2022-2-20

[5]
[Guidelines on the diagnosis and management of primary sclerosing cholangitis (2021)].

Zhonghua Nei Ke Za Zhi. 2021-12-1

[6]
UPDATE OF THE BRAZILIAN SOCIETY OF HEPATOLOGY RECOMMENDATIONS FOR DIAGNOSIS AND MANAGEMENT OF AUTOIMMUNE DISEASES OF THE LIVER.

Arq Gastroenterol. 2019-8-13

[7]
Guideline for the evaluation of cholestatic jaundice in infants: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition.

J Pediatr Gastroenterol Nutr. 2004-8

[8]
[Guidelines on the diagnosis and management of primary biliary cholangitis (2021)].

Zhonghua Gan Zang Bing Za Zhi. 2022-3-20

[9]
Guideline for the Evaluation of Cholestatic Jaundice in Infants: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition.

J Pediatr Gastroenterol Nutr. 2017-1

[10]
Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update.

World J Gastroenterol. 2016-11-14

引用本文的文献

[1]
Therapeutic Options for the Management of the Cholestatic Phase of Viral Hepatitis A and E-A Systematic Review.

J Clin Exp Hepatol. 2025

[2]
Efficacy and Safety of Ileal Bile Acid Transport Inhibitors in Inherited Cholestatic Liver Disorders: A Meta-analysis of Randomized Controlled Trials.

J Clin Exp Hepatol. 2025

[3]
Hepatotoxicity in Cancer Immunotherapy: Diagnosis, Management, and Future Perspectives.

Cancers (Basel). 2024-12-29

[4]
Prolonged Direct Hyperbilirubinemia Following Acute Hepatitis: When Not to Worry?

J Clin Transl Hepatol. 2024-12-28

[5]
The non-HDL-C to APOB ratio as a predictor of inaccurate LDL-C measurement in patients with chronic intrahepatic cholestasis and jaundice: a retrospective study.

PeerJ. 2024

[6]
Effectiveness of oral methylprednisolone as adjuvant therapy for clinical improvement, biochemical markers, and inflammation in infants with cholestasis.

Heliyon. 2024-7-14

[7]
Progress in the Management of Patients with Cholestatic Liver Disease: Where Are We and Where Are We Going?

J Clin Transl Hepatol. 2024-6-28

[8]
Population pharmacokinetics and individualized dosing of tigecycline for critically ill patients: a prospective study with intensive sampling.

Front Pharmacol. 2024-1-29

[9]
Papaverine attenuates the progression of alpha naphthylisothiocyanate induce cholestasis in rats.

Curr Res Pharmacol Drug Discov. 2024-1-28

[10]
Cholestatic HCV Cryoglobulinemia: A New Clinical and Pathological Entity before and after Direct-Acting Antiviral Therapies-A Case-Control Study.

Int J Mol Sci. 2024-1-8

本文引用的文献

[1]
Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study.

Lancet. 2021-10-30

[2]
A homozygous R148W mutation in Semaphorin 7A causes progressive familial intrahepatic cholestasis.

EMBO Mol Med. 2021-11-8

[3]
Fibrotic Events in the Progression of Cholestatic Liver Disease.

Cells. 2021-5-5

[4]
Statins, Fibrates, and Other Peroxisome Proliferator-Activated Receptor Agonists for the Treatment of Cholestatic Liver Diseases.

Gastroenterol Hepatol (N Y). 2020-1

[5]
Cholestasis-Associated Pruritus and Its Pruritogens.

Front Med (Lausanne). 2021-3-9

[6]
Biomarkers of cholestasis.

Biomark Med. 2021-4

[7]
Current Treatment Options for Cystic Fibrosis-Related Liver Disease.

Int J Mol Sci. 2020-11-14

[8]
Managing cognitive symptoms and fatigue in cholestatic liver disease.

Expert Rev Gastroenterol Hepatol. 2021-3

[9]
Cholestatic Liver Diseases: A Primer for Generalists and Subspecialists.

Mayo Clin Proc. 2020-10

[10]
An update on the management of cholestatic liver diseases.

Clin Med (Lond). 2020-9

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索